A new analysis finds that more than $14 billion in clean energy projects in the U.S. have been canceled this year.

Teva outlines acceleration path into a leading biopharma companyInnovative medicines franchise on track to exceed $5 billion by 2030, led by AUSTEDO® (deutetrabenazine), AJOVY® (fremanezumab), UZEDY® ...